CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

June 23rd, 2014

FDA: Risk for Venous Thromboembolism with All Testosterone Products

The FDA is requiring an expanded label change to all approved testosterone products to warn of the increased risk for venous thromboembolism. Labels currently address the risk for clots associated with polycythemia caused by testosterone treatment.

The action follows reports of blood clots in testosterone users unrelated to polycythemia. The agency says the warning is not related to an ongoing investigation announced in January about possible cardiovascular risks associated with testosterone treatment.

Categories: General, Vascular
Tags: , ,


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

2 Responses to “FDA: Risk for Venous Thromboembolism with All Testosterone Products”

  1. Steve Parcell, ND says:
    June 25, 2014 at 9:50 am

    Its likely due to increased estrogen levels. Estradiol should be between 20 pg/ml and 30 pg/ml in males testosterone replacement patients. Estrogen can be lowered by giving anastrozole (Arimidex) 0.5 mg q 7days. In 11 years of managing patients on testosterone I have never seen a DVT but I am sure they do happen. Factors known to increase aromatase activity include increased age, obesity, elevated insulin (insulin resistance), gonadotropins, and alcohol.

  2. Dr Sachin Kuchya, MBBS MD DNB says:
    June 26, 2014 at 11:31 pm

    apart from these valid factors, the route of administration also matters. testosterone being liable to high first pass metabolism, gets rapidly converted to estradiol & hence low systemic Bioavailability.

    the orally adminstered preparations of testosterone are usually dosed keeping in view of this kinetics.

    therefore, topical testosterone patches could be safe, in respect of occurence of VTE.